Clinical Trials Logo

HER2-negative Breast Cancer clinical trials

View clinical trials related to HER2-negative Breast Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04901299 Withdrawn - Clinical trials for Metastatic Breast Cancer

Fulvestrant + Neratinib In Breast Cancer

HER2-Signal
Start date: July 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer. - This research study involves the study drug Neratinib - The standard of care drug Fulvestrant

NCT ID: NCT01100489 Withdrawn - Clinical trials for HER2-positive Breast Cancer

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Start date: February 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II clinical trial is studying how well breast-conserving surgery followed by radiation therapy works in treating patients with stage I or stage II breast cancer.